Samsung Biologics Co.,Ltd. (207940.KS), a contract development and manufacturing organization, on Wednesday reported higher earnings for the first quarter, supported by revenue growth.
Operating profit increased to KRW 580.8 billion from KRW 430.2 billion last year.
EBITDA (earnings before interest, taxes, depreciation and amortization) rose to KRW 675.3 billion from KRW 514.6 billion a year earlier.
Revenue grew to KRW 1.257 trillion from KRW 999.5 billion in the previous year.
Looking ahead, the company said it is on track to meet its full-year outlook.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.